|
業務類別
|
Biotechnology |
|
業務概覽
|
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems. |
| 公司地址
| 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065 |
| 電話號碼
| +1 650 649-3530 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.coherus.com |
| 員工數量
| 147 |
| Mr. Bryan J. McMichael |
Chief Financial Officer and Principal Accounting Officer |
美元 543.69K |
20/04/2026 |
| Mr. Dennis M. Lanfear |
President, Chief Executive Officer and Chairman of the Board |
美元 1.03M |
20/04/2026 |
|
|
| Ms. Rita A. Karachun |
Independent Director |
20/04/2026 |
| Dr. Jill O’Donnell-Tormey |
Independent Director |
20/04/2026 |
| Mr. Charles W. Newton |
Independent Director |
20/04/2026 |
| Dr. Lee N. Newcomer, M.D. |
Independent Director |
20/04/2026 |
| Mr. Ali J. Satvat |
Independent Director |
20/04/2026 |
| Mr. Mats L. Wahlstrom |
Lead Independent Director |
20/04/2026 |
| Mr. Dennis M. Lanfear |
President, Chief Executive Officer and Chairman of the Board |
20/04/2026 |
| Ms. Georgia L. Erbez |
Independent Director |
20/04/2026 |
| Dr. Michael Ryan, Pharm.D. |
Independent Director |
20/04/2026 |
|
|
|
|
